文献速递基础与转化研究临床试验与 GCP

CAR T细胞疗法的非典型及致死性毒性

Noncanonical and mortality-defining toxicities of CAR T cell therapy.
PubMed 文献 · Nat Med · 2025-07-16

本文综述了CAR T细胞疗法在细胞因子释放综合征(CRS)和免疫效应细胞相关神经毒性综合征(ICANS)之外的致死性及罕见毒性,讨论其机制包括靶向损伤、细胞因子相关炎症和恢复失调,并明确未满足需求与未来研究方向。

要点

  • CRS和ICANS的共识分级系统已推动标准化治疗并降低急性毒性负担。
  • 新靶点、新疾病和更广泛人群(包括长期生存者)使CAR T毒性谱不断扩展。
  • 需理解致死性及罕见毒性的机制并标准化报告以改善临床管理。

核心结论

  • CAR T细胞疗法具有独特的毒性谱,除CRS和ICANS外,致死性及罕见毒性的机制认识和标准化报告仍需加强。

研究设计与样本

  • 综述,总结CAR T细胞疗法致死性及罕见毒性的当前知识状态。

主要发现

  • CRS和ICANS的共识分级系统已促成基于严重程度的标准化治疗协议,有助于降低急性毒性负担并支持门诊给药。
  • 对CAR T细胞疗法的理解已扩展至新靶点、新疾病和更广泛患者人群,包括长期生存者。
  • 致死性及罕见毒性机制涉及靶向损伤、细胞因子相关炎症和恢复失调,这些机制影响毒性的发生时间和管理。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chimeric antigen receptor (CAR) T cell therapy is associated with a unique spectrum of toxicities that drive morbidity, mortality and patient quality of life. Previous efforts yielded consensus grading systems for the prototypical immunotoxicities-namely, cytokine-release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). These grading systems set the stage for severity-based and standardized treatment protocols that have contributed to a reduction in the acute toxicity burden of CAR T cell therapy and have enabled outpatient administration. However, understanding of CAR T cell therapy has since grown to encompass new targets, new diseases and broader patient populations-including long-term survivors. As side effects are better defined and novel toxicities emerge, there is a need to understand their mechanisms and standardize reporting to improve clinical management. Here we review the current state of knowledge for mortality-defining and rare toxicities of CAR T cell therapies, beyond CRS and ICANS. We discuss mechanisms, including on-target injury, cytokine-associated inflammation and dysregulated recovery, and how these mechanisms affect the timing and management of toxicities. Finally, we define key unmet needs and delineate future priorities and research directions.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Rejeski K, Hill JA, Dahiya S, et al. Noncanonical and mortality-defining toxicities of CAR T cell therapy. Nat Med. 2025. PMID: 40670774. doi:10.1038/s41591-025-03813-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。